AOD-9604 vs Mazdutide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal region spanning amino acids 176-191 with an additional tyrosine at position 177. It was designed to isolate the fat-metabolizing properties of hGH without the IGF-...
Calculate AOD-9604 dose →Mazdutide (IBI362) is a once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics. By activating both receptors simultaneously, it combines the appetite suppression and insulin-sensitizing effects of GLP-1 agonism with the fat-oxidizing and energy-expenditu...
Calculate Mazdutide dose →| Parameter | AOD-9604 | Mazdutide |
|---|---|---|
| Category | Metabolic & Mitochondrial | Metabolic & Mitochondrial |
| Research | Phase IIb (Discontinued) | Phase III (China) |
| Half-Life | ~30 minutes | ~7 days |
| Typical Dose | 300 µg | 3–9 mg |
| Frequency | Once daily (fasted) | Once weekly |
| Route | Subcutaneous / Oral | Subcutaneous (weekly) |
| FDA Status | Not Approved | Not Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.